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Abstract
Background—The BIO14.6 hamster provides a useful model of hereditary cardiomyopathies
and muscular dystrophy. Previous delta-sarcoglycan (δSG) gene therapy (GT) studies were limited
to neonatal and young adult animals, and prevented the development of cardiac and skeletal
muscle dysfunction. GT of a pseudo-phosphorylated mutant of phospholamban (S16EPLN)
moderately alleviated the progression of cardiomyopathy.
Methods and Results—We treated 4 month-old BIO14.6 hamsters with established cardiac
and skeletal muscle diseases intravenously with a serotype-9 adeno-associated viral vector
carrying δSG alone or in combination with S16EPLN. Prior to treatment at age 14 weeks, the left
ventricular (LV) fractional shortening by echocardiography was 31.3% vs. 45.8% in normal
hamsters. In a randomized trial, GT halted progression of LV dilation and LV dysfunction. Also,
respiratory function improved. Addition of S16EPLN had no significant additional effects. δSG-
GT prevented severe degeneration of the transverse tubular system in cardiomyocytes (electron
tomography), and restored distribution of dystrophin and caveolin-3. All placebo-treated hamsters,
except animals removed for the hemodynamic study, died with heart failure between 34 and 67
weeks of age. In the GT group, signs of cardiac and respiratory failure did not develop, and
animals lived for 92 weeks or longer, an age comparable to that reported in normal hamsters.
Correspondence to: Masahiko Hoshijima, University of California San Diego, 9500 Gilman Dr., #0734, La Jolla, CA 92093-0734,




This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing
this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it
is published in its final citable form. Please note that during the production process errors may be discovered which could affect the
content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Circ Heart Fail. Author manuscript; available in PMC 2013 August 13.
Published in final edited form as:













Conclusions—GT was highly effective in BIO14.6 hamsters even when given in late stage
disease, a finding that may carry implications for the future treatment of hereditary cardiac and
muscle diseases in humans.
Keywords
gene therapy; cardiomyopathy; muscles; heart failure; ventilation
Inherited forms of muscular dystrophy including the Duchenne/Becker Muscular
Dystrophies (DMD/BMD) (i.e. dystrophinopathies) and Limb-Girdle Muscular Dystrophies
(LGMDs) commonly affect both skeletal and cardiac muscles 1. While progressive
weakness of neck, trunk, and limb muscles are disabling in such patients, cardiac
complications and respiratory failure are major determinants of prognosis 2, 3. Among the
genes mutated in inherited muscular dystrophies, most encode membrane-cytoskeletal
proteins that constitute a macro-molecular complex termed the dystrophin-glycoprotein
complex (DGC) 1.
BIO14.6 hamsters have a spontaneous genetic deletion around the first exon of the δ-
sarcoglycan (δSG) gene 4, 5, mutations of which have been linked to human LGMD type
2F 1. Due to the absence of δSG, BIO14.6 hamsters are unable to form the sarcoglycan (SG)
protein complex, a subcomponent of the DGC, on the sarcolemma. Although BIO14.6
hamsters appear normal when born, they die early, with life-span of approximately 12
months, primarily due to the development of severe congestive heart failure 6.
Phenotypic consistency has made the BIO14.6 hamster a preferred animal model of
muscular dystrophy and hereditary cardiomyopathy used for testing new therapies, including
gene replacement using viral vectors 7-12. However, previous experimental trials of gene
therapy (GT) in BIO14.6 hamsters 7-12 and one trial in mice 13 have focused on the short or
long-term effectiveness of disease prevention by treating SG deficiency early in life
(neonatal and young adult animals, up to 9 weeks of age), and the effects of GT in late stage
disease, when cardiac and respiratory dysfunction are well established, have not been
examined.
In the present study, we delivered the δSG gene using an adeno-associated virus serotype 9
(AAV9) vector by intravenous bolus injection, allowing us to test the efficacy of GT in both
the cardiac and skeletal muscles in 4 month old BIO14.6 hamsters with well established
cardiac and respiratory failure. In addition, since a substantial number of cardiomyocytes are
lost by 4 months of age 14, 15 and surviving cells are under stress, we added an additional
group of BIO14.6 hamsters in which GT with a pseudo-phosphorylated mutant (S16E) of
phospholamban (PLN) was combined with δSG GT. Based on our previous studies in
BIO14.6 hamsters 16 and post-infarction rats 17, we expected that the positive inotropic
effect of S16EPLN treatment could further enhance any benefits from δSG GT alone.
Methods
Additional details are available on-line in “Expanded Methods”.
Animals
Male BIO14.6 hamsters and golden Syrian hamsters were obtained from Bio Breeders Inc
(Watertown, MA). All animal-related procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of California San Diego.
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The same δSG and S16EPLN expression module that was prepared in our previous
studies 11 was utilized.
Gene transfer procedures
BIO14.6 hamsters (80-100 gram body weight) were anesthetized with ketamine (100 mg/
Kg) and xylazine (2.5 mg/kg). Through a small incision in the left inguinal region, the
femoral vein was exposed and cannulated with flame-stretched polyethylene tubing (PE-50,
Becton-Dickinson, Parsippany, NJ) and AAV9 vectors (8×1011 viral genome particles per
100 gram of body weight) were delivered.
Assessment of cardiac function
The methods for transthoracic echocardiographic analysis of left ventricular (LV) function
and retrograde LV catheterization using a micro-manometer in anesthetized hamsters have
been described 18. Examiners were blinded to the treatments.
Assessment of respiratory function
A barometric method of plethymography with continuous flow 19 was used to calculate tidal
volume and minute ventilation in spontaneously breathing, non-anesthetized hamsters.
Hypercapnia-induced ventilation estimated the additional capacity of animals to respond to a
ventilatory stimulus.
Electron microscopy
The sample preparation procedures have been described 20. Electron tomography was
obtained in thick sections (500 nm) using an intermediate high-voltage EM system (400
kV). The tomographic reconstruction was carried out as described 20.
Immuno-fluorescent staining
Snap-frozen heart tissues were cryo-sectioned and unfixed specimens were stained using an
indirect immuno-fluorescence strategy as described 18.
Statistics
Comparison between groups used a mixed-effects linear model or a repeated-measures two-
factor ANOVA with post hoc tests. Values are mean±SEM, unless stated differently.
Results
The study design is shown in Figure 1A. We treated 16-week old male BIO14.6 hamsters
with intravenous injection of an AAV9 vector carrying a human copy of the δSG gene
(δSG/AAV9), δSG/AAV9 in combination with S16EPLN carried by an AAV9 vector
(S16EPLN/AAV9), and placebo (saline injection). S16EPLN treatment was shown in our
previous study to be moderately effective in reducing the degree of heart failure in BIO14.6
hamsters over 7 months 16. We chose saline-treatment as control based on a finding that
echocardiography detected no functional difference between saline-treated animals and
animals treated with an AAV9 vector carrying lacZ β-D-galactosidase (n=5 each group)
over 6 months (data not shown).
AAV9 vectors are known to effectively transduce genes in cardiac muscle 21-24. Prior to
gene transfer, echocardiographic assessment at 14 weeks of age confirmed that left
ventricular (LV) function in these BIO14.6 hamsters was substantially depressed compared
to age-matched normal golden Syrian hamsters: the % fractional shortening (%FS) was
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31.3±4.89% in the BIO14.6 (n=30) vs. 45.8±2.85% in the normal controls (n=6), (P<0.001)
(Figure 2A, Pre). Enlargement of the LV chamber was not yet statistically significant at this
age (Figure 2B, Pre). However, the LV end-diastolic wall stress estimated by the LV end-
diastolic dimension/posterior wall thickness ratio (LVEDd/PWTh) in BIO14.6 hamsters 16
was twice that in normal hamster (7.19±0.15, n=30, vs. 3.78±0.20, normal hamsters, n=6,
P<0.001) (Figure 2D). No early mortality or procedure-related health problems were
observed after the gene transfer procedure.
The efficiency of δSG replacement was nearly 100% both in ventricular cardiomyocytes
(Figure 1C and D) and in fast-twitch skeletal muscles including quadriceps (Figure 1F),
anterior tibial, and extensor digitorum longus muscle (data not shown). The efficiency was
slightly lower in slow-twitch muscles, such as soleus (Figure 1G). No δSG expression was
detectable in non-muscle organs/tissues including liver, lung, kidney, and brain (Figure 1H-
K), and the LV coronary vascular system was devoid of staining.
δSG gene transfer halted the development of cardiac failure
After initial echocardiographic studies, the hamsters were randomly separated into
subgroups (10 δSG/AAV9-treated animals, 10 δSG/AAV9 and S16EPLN/AAV9-treated,
and 10 saline-treated placebo animals) (Figure 1A).
Placebo-treated group—By 25 weeks after placebo treatment, the general health of the
BIO14.6 hamster in the placebo was deteriorating, by developing physical weakness
including markedly reduced spontaneous activity and poor appetite, and clinical signs of
congestive heart failure including dyspnea and anasarca.
One animal died at 18 weeks after the placebo-treatment, and the %FS of the other placebo
animals had declined by 25 weeks by an average of 56%, to 13.8±2.13% (n=9) (Figure 2A).
The placebo group developed severe LV chamber dilation (Figure 2B). The LV wall
thickness remained markedly thinned (Figure 2C), and therefore the estimated diastolic wall
stress continuously increased in this group (Figure 2D). Late echocardiographic studies (49
and 65 weeks after treatment) were not obtained for the placebo group. After 5 randomly
selected animals were, as scheduled, removed and used for a hemodynamic study at 28
weeks together with other GT-treated animals, all remaining placebo animals died or were
severely morbid by the time of the late echocardiography.
GT Groups—Both BIO14.6 hamsters treated with δSG/AAV9 alone and those treated with
δSG/AAV9 and S16PLN/AAV9 showed vigorous spontaneous activity, maintained good
appetite, and displayed no obvious appearance of systemic edema or respiratory distress.
Echocardiography at 25 weeks after GT showed that treatment preserved LV function
remarkably well in both treatment groups, demonstrating complete prevention of a decline in
the %FS (Figure 2A), suppression of progressive LV dilation (Figure 2B), and a significant
increase in diastolic LV wall thickness (Figure 2C) which reduced the estimated LV
diastolic wall stress relative to the placebo group (Figure 2D). The rate of decline in %FS
and the rate of LV dilation were significantly smaller in the treatment groups than in the
placebo (P<0.0001), but there was not a statistically significant difference between the δSG/
AAV9-treatment alone and the combined treatment of δSG/AAV9 and S16PLN/AAV9
(%FS, P=0.21; LVEDd, P=0.10). LV wall thickness was significantly greater at 25 weeks in
the treatment groups than in placebo (δSG/AAV9 alone, P=0.002; δSG/AAV9 and S16PLN/
AAV9, P=0.0125). Estimated diastolic wall stress did not change significantly after GT (at
25 weeks vs. pre: δSG/AAV9 alone, P=0.73; δSG/AAV9 and S16PLN/AAV9, P=0.17).
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Late-stage echocardiography (49 and 65 weeks after GT) showed that a favorable effect of
the δSG replacement therapy on cardiac function was maintained. Only mild fall in the %FS
(Figure 2A) and gradual LV chamber enlargement (Figure 2B) were recognized.
In animal groups treated with δSG/AAV9 alone and with δSG/AAV9 and S16EPLN/AAV9,
a beneficial increase in LV wall thickness observed at 25 weeks (see above), might have
served to prevent LVEDd/PWTh from increasing significantly at 49 and 65 weeks (Figure
2D).
Hemodynamic Studies—To confirm that prevention of the progressive heart failure
phenotypes by GT was due, at least in part, to a direct beneficial effect on LV function and
myocardial contractility, BIO14.6 hamsters from each treatment group (n=5 per group) were
subjected to invasive cardiac hemodynamic examination (catheter tip micromanometry) at
28 weeks after GT (at age 44 weeks) (Figure 3). At rest and with a treatment of increasing
doses of dobutamine, the maximum first derivative of LV pressure (max LV dP/dt), an index
of LV myocardial contractility, was significantly higher in both of the treated groups
compared to the placebo group (Figure 3A). GT also caused marked enhancement of LV
relaxation, reflected in an increase in the peak negative first derivative of LV pressure (min
LV dP/dt) (Figure 3C) and a shorter time constant of LV pressure decay (tau) (Figure 3D), a
relatively load independent measure of relaxation.
δSG gene transfer halted deterioration of respiratory function
Most of the placebo-treated BIO14.6 hamsters showed clinical signs of severe respiratory
distress before they died. Although lung congestion secondary to heart failure can be the
cause of dyspnea, respiratory muscles are among the most severely affected skeletal muscles
in BIO14.6 hamsters 14, 15. Therefore, we combined the 84-86 weeks old δSG/AAV9-
treated animals with (n=4) and without (n=3) S16EPLN treatment and applied whole body
plethysmography in wake animals breathing spontaneously. Because untreated BIO14.6
hamsters do not survive to this age, we studied 42-46 weeks old BIO14.6 hamsters as
controls without GT. Golden Syrian hamsters (42-46 weeks old) served as normal controls.
Untreated group—Basal respiratory function (tidal volume and minute ventilation) was
mildly depressed in the non-treated group compared to normal hamsters (Figure 4 A and B).
However, the hypercapnic ventilatory response to 8% CO2 was severely impaired. The tidal
volume increased by only 45%, compared to highly significant increases (81%) in normal
hamsters (Figure 4A). Hypercapnia also inefficiently stimulated minute ventilation of non-
treated BIO14.6 hamsters (Figure 4B).
GT group—The basal tidal volume of GT-treated BIO14.6 hamsters was not significantly
different from that in normal hamsters (Figure 4A). In 8% CO2, tidal volume increased by
66% and minute ventilation increased by 117%, to a functional level that was not
significantly different from that measured in younger normal hamsters (Figure 4 A and B).
There was no significant difference between the three animal groups (normal hamsters,
BIO14.6 hamsters, and GT-treated BIO14.6 hamsters) with respect to respiratory frequency,
both at rest and after receiving hypercapnic stimulation.
Efficiency of δSG replacement in respiratory muscles—GT restored δSG in
respiratory muscles (diaphragm and the intercostal muscle: ICM), and efficiency was nearly
100% in ICM (Figure 4D and H), although δSG expression was lower and inhomogeneous
in the diaphragm (Figure 4F and J). In addition, αSG and βSG immuno-staining was
observed on the sarcolemma in treated BIO14.6 hamsters (data not shown), confirming that
the SG complex was restored on the sarcolemma in respiratory muscles.
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δSG gene transfer preserved ultrastructure and subcellular components in cardiac muscle
Degeneration of the transverse tubular system (T system) was ameliorated—
δSG is known to localize both on the peripheral sarcolemma and along the T system 25, 26
(Figure 1C and D). Therefore, using an advanced 3-dimensional (3-D) electron microscopic
technology (electron tomography), we characterized T system abnormality, which was
previously reported27.
As shown in Figure 5D and F (see also Video 1), high-resolution electron tomography
(voxel size: 1.42 nm × 1.42 nm × 1.42 nm) revealed a strikingly deformed cardiac T system
in placebo-treated BIO14.6 hamsters. Interestingly, multiple cystic invaginations with
diameters of 75-100 nm were observed on T system membranes (Figure 5F). Such T system
abnormalities were absent in BIO14.6 hamsters treated with δSG replacement (Figure 5 C,
E, and G).
DGC was reconstituted—Despite preceding focal lytic changes in the myocardium, δSG
GT effectively recruited and stabilized αSG (Figure 6 C and F), as well as βSG and γSG
(data not shown), on the sarcolemma of surviving cardiomyocytes; the SGs were restored on
both the peripheral sarcolemma and the internal sarcolemma of the T system. δSG
replacement also favorably affected the entire DGC, including the correction of the
abnormal distribution of dystrophin at intercalated discs (Figure 6 I and H), which was
reported previously 18. β-dystroglycan (β-DG) is considered to serve as an intermediate
molecule connecting the SG complex and dystrophin 1; however, the subcellular distribution
of β-DG (Figure 6 J-L) did not coincide with dystrophin redistribution (Figure 6 G-I).
δSG GT prevented changes in caveolin-3 (Cav3) distribution—Because the
multiple micro cystic invaginations of the T system membranes found on electron
tomography resemble caveolae (see Discussion), we analyzed the distribution of Cav3, a key
molecule in the formation of caveolae in cardiac muscle 28 using immuno-staining.
Unexpectedly, T system-associated Cav3 staining was greatly reduced in untreated BIO14.6
hamsters, while the punctate staining pattern of Cav3 along the peripheral sarcolemma
remained (Figure 7 B, E, and H). This abnormal Cav3 distribution was not seen in the δSG/
AAV9-treated BIO14.6 hamsters (Figure 7 C, F, and I).
GT prolonged the lifespan of BIO14.6 hamsters
As noted above, due to the development of severe symptoms of cardiac and respiratory
failures, none of placebo-treated BIO14.6 hamsters (n=5) survived to undergo late
echocardiography. These animals died of the heart failure between 34 and 67 weeks of age.
In contrast, there was no animal loss in the GT-treated groups (n=10) until one animal was
found dead at 92 weeks of age, followed by two animals at 93 weeks. These animals showed
gradual reduction of activity but did not present obvious signs of heart failure or respiratory
distress. Kaplan-Meier analysis with the log-rank test revealed significant improvement in
animal survival in the treatment groups (each group, P=0.004). The addition of S16EPLN/
AAV9 treatment provided no additional benefit (P=0.48). It should be noted that the late
deaths at 92 and 93 weeks are within the reported lifespan of the normal Syrian hamster,
82±25 weeks in one study 29 and 106±26 weeks (mean±SD) in another study 30. The
remaining 7 animals in the GT group were euthanized at 96 weeks in order to perform tissue
studies.
Discussion
While previous gene therapy trials treated young BIO14.6 hamsters and δSG-null mice
before the onset or at an early stage of the disease 7-13, we chose 16 weeks of age in the
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current study as the time for GT in BIO14.6 hamsters when LV dysfunction is moderately
severe 18. In the BIO14.6 hamster, the lytic changes in the myocardium and respiratory
muscles become evident by 20-40 days of age 15 and subside by 150-160 days to be replaced
by fibrosis and calcification14, 15. The progression of cardiac and skeletal muscle weakness
lags somewhat behind histological changes 14, 15. For example, the LV was not significantly
dilated and the %FS was only mildly reduced (37-40%) just prior to treatment in our
previous δSG GT trial in 7 to 9 week old BIO14.6 hamsters 8. In addition, myopathic
changes do not appear until 3 months of age in δSG-null mice 31, which were treated in a
previous GT study 13. Accordingly, this study appears to be the first to show that GT at a
relatively advanced stage of disease in this form of hereditary cardiac and skeletal myopathy
can halt the rapid progression of clinical signs and echocardiographic findings of LV
dysfunction, ameliorate many of the structural abnormalities in cardiac muscle, and
favorably affect survival.
We consider that the failure of the S16EPLN treatment to provide an additional effect in the
current study is primarily due to the overwhelming efficacy of δSG GT. In addition, the
efficacy of S16EPLN therapy is sensitive to the stoichiometry of sarcoplasmic reticulum
calcium-ATPase and native PLN molecules 16, which might not be optimal in the current
study, where recipient BIO14.6 hamsters were much later into treatment than in our earlier
study 16.
We believe that this study provides the initial demonstration of a successful in vivo
treatment of respiratory dysfunction by GT in a muscular dystrophy model. Since cardiac
function and lung function are highly interrelated 32, 33, we speculate that the improvement
of respiratory function found in the current study is probably due to both a direct effect of
GT on respiratory muscles and a secondary effect from improved cardiac function.
The study also applied electron tomography 20, 34 and revealed an enormous T-system
dilation and multiple small cystic invaginations associated with the T-system in placebo-
treated BIO14.6 hamsters (Figure 5 D and F). From their size and shape, we initially
speculated that these cystic membrane structures represented caveolae 35, 36. Caveolae are
frequently observed on the peripheral sarcolemma of cardiac myocytes 35 and at the tips of
elongating cardiac T-tubules in young mammals 37. In the past, caveolae were thought to be
the precursor of T-tubules 38. However, this is unlikely in this case, since Cav3, which is
prerequisite for caveola formation in striated muscles 28, was found to be dissociated from
the T system in BIO14.6 hamsters (Figure 7 E and H). The cause of Cav3 dislocation is not
clear, as Cav3 may not be an integral component of the DGC 39. Nonetheless, it remains
possible that the translocation of Cav3 might be a factor leading to disorganization of the
cardiac T system in BIO14.6 hamsters, as suggested in studies in humans with LGMD 40.
There is an increasing awareness of the clinical importance of cardiac involvement in
muscular dystrophy 2, 3. Currently, cardiac and skeletal muscles are often significantly
damaged when patients are first diagnosed, despite increasing use of newborn screening 41.
The δSG-deficient BIO14.6 hamster used in the current study develops myolysis and
progressive weakness in both cardiac and skeletal muscles resembling the clinical
manifestation of DMD/BMD. Also, plasma membrane fragility has been suggested as the
central disease mechanism of dystroglycanopathies and genetic SG defects, as recently
reviewed1. Importantly, recent improvements in health care practices have extended the
lifespan of DMD/BMD patients and, as a result, nearly 90% of DMD/BMD patients now die
from cardiac or muscular respiratory failure 2. Accelerated cardiac damage found in
dystrophin-deficient mice that were selectively treated for skeletal muscle myopathy further
supports the need for cardiac therapy in muscular dystrophy 42. In addition, approximately
25% of all so-called idiopathic cardiomyopathies in humans are genetic, and these
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individuals might not be identified at an early disease stage by family studies and/or genetic
screening 43. Therefore, we consider that the therapeutic efficacy of relatively late gene
replacement demonstrated in the present study carries significant clinical implications for
the future of GT in humans, even when cardiac and respiratory dysfunction are well
established.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Systemic induction of δSG in BIO14.6 hamsters using an AAV9 vector
A shows the time course of the study. The human copy of δSG was systemically transferred
intravenously to BIO14.6 hamsters at the age of 16 weeks, with or without a pseudo-
phosphorylated mutant PLN (S16EPLN), both carried by an AAV9 vector. GT, gene
transfer. B and E show negative δSG immuno-staining in left ventricular and quadriceps
muscles in placebo (saline)-treated BIO14.6 hamsters. C, D, and F-K are representative δSG
immuno-staining in various tissues collected from δSG/AAV9-treated BIO14.6 hamsters at
28 weeks (wks) after gene transfer. D is a high magnification view of a subarea of C (dashed
line square). δSG induction was confirmed on both the peripheral sarcolemma and the T
system (D). Bars, 10 μm in B-F, 100 μm in G-K.
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Figure 2. δSG replacement with S16EPLN therapy prevented the progression of cardiac
dysfunction and chamber dilation in BIO14.6 hamsters
Normal, placebo-treated, and BIO14.6 hamsters treated with the δSG/AAV9 alone or in
combination with S16EPLN/AAV9 (denoted as BIO δSG and BIO δSG+S16E,
respectively) were followed by serial echocardiograms. A shows preservation of %FS with
treatment, as an index of LV systolic function. B indicates prevention of LV dilation with
treatment. C demonstrates changes in diastolic LV wall thickness. In D, estimated diastolic
wall stress (LVEDd/PWTh) is significantly reduced by the treatment (relative to the
placebo). See the text for details. The blue dashed lines are pair-wise comparisons between
animal groups tested by a mixed-effects linear model (*P<0.05 or “n.s.”). Depressed cardiac
function of BIO14.6 hamsters prior to the treatment was shown (#P<0.05, vs. normal at pre-
GT). Error bars are means±SEM. Pre, pre-GT; n.s., no significance.
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Figure 3. Chronically improved cardiac contractility and relaxation by δSG replacement
therapy in BIO14.6 hamsters
BIO14.6 hamsters treated with δSG/AAV9 alone or in combination with S16EPLN/AAV9
(BIO δSG and BIO δSG+S16E, respectively) for 28 weeks were subjected to hemodynamic
analyses. At rest (dobutamine, 0 μg/Kg/min) measures of LV contractility (max LV dP/dt)
shown in A and relaxation (min LV dP/dt and tau) shown in C were significantly higher in
treated animals than in placebo-treated controls. Since min LV dP/dt is sensitive to changes
in peak LVP, tau (a relatively load-independent index of relaxation) was also evaluated (D)
and improved at rest in the GT groups. Dobutamine enhanced LV systolic and diastolic
functions dose-dependently in both placebo and GT groups. The blue dashed lines are pair-
wise comparisons between animal groups (*P<0.05 or “n.s.”). #P<0.05, vs. placebo at rest.
Error bars are means±SEM. n.s., no significance.
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Figure 4. δSG replacement improved respiratory function and restored the SG complex on the
respiratory muscle sarcolemma
A and B show ventilatory function in BIO14.6 hamsters (84-86 weeks old, n=7) treated with
δSG/AAV9 at 16 weeks of age, with and without additional S16EPLN treatment, compared
to that of untreated younger BIO14.6 hamsters and normal golden hamsters (42-46 weeks
old, n=6 in each group). In both tidal volume (A) and minute ventilation (B) measurements,
beneficial therapeutic effects are shown at rest (Basal) and after exposure to hypercapnia
(8% CO2). The mean values of measurements in treated hamsters are statistically
indistinguishable from those measured in younger normal hamsters. Unadjusted p-values of
pair-wise comparisons are shown in A and B. # p-value is smaller than the critical level of
significance. * p-value is smaller than the critical level of significance, vs. basal. The Error
bars are means±SEM. Representative immuno-staining of restored δSG is shown in the
diaphragm (F and J) and intercostal muscles (ICM, D and H). C, G, E and I show absence of
SG staining in placebo-treated BIO14.6 hamsters. G-J show δSG staining alone. In C-F,
sarcolemmal staining with WGA (green) and nuclear staining with DAPI (nuc, blue) are co-
visualized. Bars, 100 μm.
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Figure 5. Degeneration of the cardiac T system in BIO14.6 hamsters demonstrated by electron
tomography
A-C, 70-nm thin-section electron micrographs. T, T-tubule. L, lipid droplet. In B, arrows
indicate dilated T-tubules in BIO14.6 cardiomyocytes treated with placebo for 28 weeks,
compared to normal T-tubules found in golden Syrian hamsters (A) and in BIO14.6
cardiomyocytes treated with δSG/AAV9 alone (C). D-G are composite images of 3-D
surface-rendered mesh models of T system (green) and dyadic junctions (red) with 2-
dimensional slices, generated from reconstructed electron tomograms. F and G are high
magnification views of outlined volumes in D and F (white dashed lines), respectively.
Arrows in F indicate multiple “caveola”-like cystic invaginations of the T system
membrane. The size of tomograms is 5.8 × 5.4 × 0.36 μm3 (placebo) and 5.8 × 5.5 × 0.27
μm3 (δSG treated), respectively. See Video 1.
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Figure 6. Reconstitution of the DGC by δSG GT in cardiomyocytes
LV tissues were collected from BIO14.6 hamsters after 28-weeks of treatment with δSG/
AAV9 alone. The effect of δSG/AAV9 treatment (C, F, I, and L) in BIO14.6 hamsters was
referenced to placebo treatment (B, E, H, and K) and normal golden Syrian hamsters (A, D,
G, and J). D-F show αSG staining (red) alone. A-C show combination of αSG staining (red)
with membrane staining with WGA (green), which stains both the peripheral sarcolemma
and T system, and nuclear staining (nuc, blue) with DAPI. G-I shows that dystrophin is
expressed on both the peripheral sarcolemma and T system, and aberrantly expressed in
intercalated discs only in placebo-treated BIO14.6 cardiomyocytes (H, arrows). The
dystrophin expression in intercalted discs was not accompanied by change in β-DG
distribution (K). Bars, 10 μm.
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Figure 7. Aberrant distribution of Cav3 in BIO14.6 hamster cardiomyocytes, which was restored
by δSG replacement
A-C show Cav3 immno-staining (red), together with sarcolemmal staining with WGA
(green) and nuclear staining with DAPI (nuc, blue). D-I are Cav3 immno-staining only (red).
G-I represent high magnification of D-F, respectively (dashed line square). T system-
associated distribution of Cav3 in normal hamsters (arrow heads in G) is largely lost in
cardiomyocytes in 28-week placebo-treated BIO4.6 hamsters (E and H). Punctate Cav3
staining on the peripheral sarcolemma (arrows in G-I) is, on the other hand, preserved (H).
Abnormal Cav3 distribution was restored at 28-weeks after δSG replacement (F and I).
Bars, 10 μm.
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